What's Happening?
City Therapeutics has announced the dosing of the first participant in its Phase 1 clinical trial for CITY-RBP4, an investigational RNA interference (RNAi) therapeutic designed to treat Stargardt disease type 1 (STGD1). This marks a significant step in the development
of a potential new treatment for the genetic eye condition, which currently has no approved therapies. CITY-RBP4 is a GalNAc-conjugated small interfering RNA (siRNA) that aims to silence RBP4 expression in the liver. By reducing the production of RBP4, the primary carrier of retinol to the eye, the therapy seeks to limit vitamin A delivery and subsequently slow retinal damage and vision loss. Initial data from this first-in-human study is anticipated in mid-2027. The trial is a multicenter, randomized, double-masked, placebo-controlled study enrolling both healthy volunteers and individuals with Stargardt disease, focusing on evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple subcutaneous doses.
Why It's Important?
The initiation of this Phase 1 trial is crucial for the Stargardt disease community, as it represents a new avenue in the quest for effective treatments for this debilitating condition. Stargardt disease leads to progressive and irreversible central vision loss, often early in life, significantly impacting patients' quality of life. The FDA is currently reviewing another RBP4-targeting therapy, tinlarebant, indicating a growing focus on this pathway for treatment. CITY-RBP4's approach of silencing RBP4 expression in the liver offers a different mechanism compared to tinlarebant, which disrupts the RBP4–TTR interaction. This diversity in therapeutic strategies is vital, as it increases the chances of finding a successful treatment and provides potential alternatives for patients who may not respond to other therapies. The success of this trial could pave the way for a much-needed treatment option, offering hope to those affected by Stargardt disease.
What's Next?
City Therapeutics expects to release initial Phase 1 data for CITY-RBP4 in mid-2027. This data will be critical in determining the safety and preliminary efficacy of the RNAi therapeutic, guiding its further development. If the Phase 1 results are positive, the company will likely proceed to later-stage clinical trials to further evaluate the drug's effectiveness and long-term safety. Beyond Stargardt disease, City Therapeutics is also exploring CITY-RBP4 for geographic atrophy (GA) secondary to age-related macular degeneration, an indication for which tinlarebant is also being studied. The company has a partnership with Bausch + Lomb to develop an intravitreal RNAi candidate for retinal diseases, including GA, which includes significant milestone payments. These developments suggest a broader pipeline of RNAi therapies targeting various retinal conditions, with potential future clinical trials and regulatory submissions.
Beyond the Headlines
The development of CITY-RBP4 highlights the increasing sophistication of RNA interference (RNAi) therapies in addressing genetic diseases. By directly targeting the genetic mechanisms underlying Stargardt disease, this approach offers the potential for a more precise and effective treatment compared to traditional methods. The focus on RBP4 as a therapeutic target underscores a deeper understanding of the disease's pathophysiology, where the accumulation of toxic vitamin A byproducts plays a central role. The competitive landscape, with other RBP4-targeting therapies like tinlarebant also in development, suggests a paradigm shift in how Stargardt disease is being approached, moving towards disease-modifying treatments rather than just symptomatic management. This could set a precedent for treating other genetic eye conditions and rare diseases, demonstrating the power of gene-silencing technologies to address previously untreatable conditions.
